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A B S T R A C T
Human infection with Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is driven by recurring dro-
medary-to-human spill-over events, leading decision-makers to consider dromedary vaccination. Dromedary
vaccine candidates in the development pipeline are showing hopeful results, but gaps in our understanding of the
epidemiology of MERS-CoV in dromedaries must be addressed to design and evaluate potential vaccination
strategies. We aim to bring together existing measures of MERS-CoV infection in dromedary camels to assess the
distribution of infection, highlighting knowledge gaps and implications for animal vaccination. We system-
atically reviewed the published literature on MEDLINE, EMBASE and Web of Science that reported ser-
oprevalence and/or prevalence of active MERS-CoV infection in dromedary camels from both cross-sectional and
longitudinal studies. 60 studies met our eligibility criteria. Qualitative syntheses determined that MERS-CoV
seroprevalence increased with age up to 80–100% in adult dromedaries supporting geographically widespread
endemicity of MERS-CoV in dromedaries in both the Arabian Peninsula and countries exporting dromedaries
from Africa. The high prevalence of active infection measured in juveniles and at sites where dromedary po-
pulations mix should guide further investigation – particularly of dromedary movement – and inform vacci-
nation strategy design and evaluation through mathematical modelling.
1. Introduction
Since the first human case of Middle East Respiratory Syndrome
Coronavirus (MERS-CoV) infection was detected in 2012 (Zaki et al.,
2012), a substantial evidence base has built up showing dromedary
camels to be the reservoir host of the virus, from which spill over to
humans can occur (FAO-OIE-WHO MERS Technical Working Group,
2018). MERS-CoV circulates extensively in dromedary populations
causing no impactful disease. Human infection, however, is associated
with a measured case fatality ratio of around 35% (World Health
Organisation, 2018a). Following spill-over events, human-to-human
transmission of MERS-CoV is relatively inefficient and limited to close,
unprotected contact environments such as hospitals (Breban et al.,
2013; Cauchemez et al., 2013). Phylogenetic analysis of viral sequences
isolated from dromedaries and humans indicates that hundreds of
camel-to-human spill-over events are likely to have occurred since 2012
(Dudas et al. 2018). Taken together, recurring dromedary-to-human
transmission is driving ongoing human infection.
The key role of dromedaries in human MERS-CoV infection has led
decision-makers to consider dromedary vaccination as part of MERS-
CoV prevention interventions (FAO-OIE-WHO MERS Technical
Working Group, 2018). Dromedary-targeted vaccine candidates in the
development pipeline are showing promising results and include an
orthopox-virus based vaccine capable of greatly reducing viral shedding
in dromedary challenge studies (Haagmans et al., 2016).
However, vaccine strategy evaluation is currently precluded by gaps
in the understanding of the epidemiology of MERS-CoV in dromedaries.
The dromedary population is highly heterogeneous and spans a wide
geographic area stretching from West Africa through to the Middle East
and parts of Asia. Knowing how infection is distributed within the po-
pulation, when and where dromedaries would need to be targeted, and
the likely impact of vaccination, is necessary before further con-
sideration of dromedary vaccination in the wider socioeconomic and
cultural context.
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Here, we systematically reviewed published studies that measured
MERS-CoV antibody seroprevalence in dromedaries and/or prevalence
of viral RNA in dromedaries. Assuming assay specificity and long-term
presence of antibodies after infection, seroprevalence can be used to
estimate what proportion of a dromedary population has ever been
infected with MERS-CoV. Broken down by age class, this can tell us
when most animals encounter the infection for the first time.
Additionally, although whole-virus isolation and culture is necessary to
confirm whether the shedding is infectious, detection of viral RNA
through Reverse Transcription Polymerase Chain Reaction (RT-PCR)
can be used as a proxy for the prevalence and distribution of infectious
dromedaries (Corman et al., 2012; OIE, World Organisation for Animal
Health, 2017; World Health Organisation, 2018b).
By conducting a qualitative synthesis of the study findings, con-
sidering reported heterogeneities, and summarising the results of
longitudinal studies of infection and immunity, we aim to assess the
extent of current understanding of MERS-CoV epidemiology in dro-
medaries, implications for control, and gaps to be addressed going
forward. We note that a similar systematic review of the literature up
until May 2018 was unknowingly carried out in parallel to our own
(Sikkema et al., 2019), with no discussion between the two groups.
Here, we validate and update the results of the parallel review, dis-
cussing our results in the context of potential animal vaccination and
mathematical modelling of MERS-CoV in dromedary camels.
2. Methods
We conducted a systematic review of studies published prior to 31st
December 2018 reporting measures of seroprevalence or prevalence of
hCoV-EMC or MERS-CoV RNA in dromedary populations by searching
EMBASE (Elsevier, 2018), MEDLINE (National Library of Medicine,
2018) and Web of Science (Clarivate Analytics, 2018b) using the search
strategy in Fig. 1. The search and the data extraction were conducted by
a single author and no publication date restrictions were imposed. For a
full list of search terms used, corresponding PRISMA flowchart and
checklist see supplementary material S1–3 respectively.
Records were excluded if they met the following criteria established
prior to the search: opinion pieces, or reviews reporting no new data,
studies investigating an aspect of MERS-CoV or another pathogen that
did not involve dromedary samples or involved experimentally in-
fecting dromedaries with MERS-CoV, and studies not available in
English. Remaining studies were categorised as longitudinal or cross-
sectional for qualitative synthesis. To address potential bias, we con-
sider studies investigating dromedary populations epidemiologically
linked to human MERS-CoV infection separately from those aiming for
random sampling.
When available, we took the results of neutralisation-based testing
over methods that determined seropositivity based on antibody
screening tests alone. Neutralising antibody tests are more specific and
are the World Organisation for Animal Health (OIE) recommended
method for confirming MERS-CoV seropositivity in dromedaries (OIE,
World Organisation for Animal Health, 2017).
We extracted RNA prevalence values determined by RT-PCR of
nasal swabs, ignoring any additional samples taken. Use of RT-PCR to
test for the presence of at least two of the established genomic regions
unique to MERS-CoV is the OIE standard for detection of active MERS-
CoV infection in dromedaries (OIE, World Organisation for Animal
Health, 2017) and viral RNA is most frequently and abundantly present
in nasal swabs compared to other non-invasive samples (Mohran et al.,
2016).
Throughout this review, we use ‘calf’ to refer to animals under one-
year-old, ‘juvenile’ ≤2 years old, and ‘adult’> 2 years old.
3. Results
Our search retrieved 802 publications. Duplicates were detected and
removed in EndNote X8.2 (Clarivate Analytics, 2018a), leaving 414
unique publications. A further 322 records were excluded during ab-
stract screening using the criteria given above. Of the remaining 92, full
text screening proved that a further 30 records met the exclusion cri-
teria. Two records sampled Bactrian camels (largely restricted to Cen-
tral Asia, they have not yet been found to have been infected with
MERS-CoV) (Chan et al., 2015; Liu et al., 2015; Miguel et al., 2016),
leaving 60 records pertaining to MERS-CoV seropositivity and/or RNA
positivity in dromedaries (Fig. 1). 55 of these described cross-sectional
studies of dromedary populations, sampling each animal at a single
time-point only (40 measured seroprevalence and 32 measured RNA
prevalence). Note that 6 studies were designed to investigate groups of
dromedaries that had been epidemiologically linked to human cases of
MERS-CoV infection rather than conducting a systematic/random
survey. Longitudinal studies that measured seropositivity and viral RNA
shedding in the same animals at multiple time-points, featured in 11
publications.
3.1. Seroprevalence – cross-sectional studies
Variously, studies conducted dedicated MERS-CoV sero-surveys,
opportunistically tested samples taken for other means, tested stored
sera or sampled dromedaries during human outbreak investigations.
Not all studies used neutralisation-based testing to determine or con-
firm seropositivity, and, between those that did, cut-off positivity titres
varied (Table 1).
Fig. 1. Review strategy. Published studies found with all three of our selected search term groups were then assessed against the exclusion criteria resulting in a
final selection of 60 publications.
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Table 1
Cross-sectional surveys of MERS-CoV seroprevalence and RNA prevalence in camels.
Ref Country Year Seroprevalence RNA prevalence Stratifications
% na Rangeb NTc % na Rangeb
(Crameri et al., 2015) Australia 2013-14 0% 307 – 1:10 – – – –
(Hemida et al., 2014b) 2014 0% 25 – 1:40 – – – –
(Islam et al., 2018) Bangladesh 2015 31% 55 – 1:20 0% 55 – age, site type, origin, sex, body condition
(Miguel et al., 2017) Burkina Faso 2015 80%d 525 73-85% 1:20 5%d 525 0-12% Region. Further factors assessed in GLMM
(Reusken et al., 2013a) Canary Islands 2012-13 9% 105 – 1:20 – – – origin
(Gutierrez et al., 2015) 2015 4% 170 – – – – – origin
(Muller et al., 2014) Egypt 1997 79% 43 – 1:80 – – – –
(Chu et al., 2014) 2013 92% 52 – 1:20 4% 110 3-30% sex
(Perera et al., 2013) 2013 94% 110 – 1:20 – – – –
(Hemida et al., 2014b) 2014 100% 8 – 1:40 – – – –
(Ali et al., 2017b) 2014-16 71% 2541 59-95%e 1:20 15% 2825 1-36%e origin, site type, sex, month
(Ali et al., 2017a) 2015-16 85% 1031 77-96%e 1:20 4% 1078 1-9%e origin, site type, sex
(Reusken et al., 2014b) Ethiopia 2010-11 96%d 188 95-100% • – – – region
(Fukushi et al., 2018) 2013 96% 66 – NA – – – –
(Miguel et al., 2017) 2015 96%d 632 85-99% 1:20 10%d 632 0-16% Region. Further factors assessed in GLMM
(Thwiny et al., 2018) Iraq 2014-15 85% 180 85-86% – – – – age, region, sex
(Al Salihi and Alrodhan, 2017) 2015-16 – – – – 15% 100 0-35% age, region, month
(David et al., 2018) Israel 2012-17 62% 411 – 1:20 0% 540 – –
(Harcourt et al., 2018) 2013 72% 71 – 1:20 – – – sex
(Shirato et al., 2015) Japan < 2015 0% 5 – 1:20 0% 4 – –
(Reusken et al., 2013b) Jordan 2013 100% 11 – 1:20 – – –
(van Doremalen et al., 2017) 2016 82%d 45 77-87% – 62% 45 48-77% age, region, lifestyle
(Miguel et al., 2016) Kazakhstan 2015 0% 455 – 1:20 – – – –
(Corman et al., 2014) Kenya 1992-2013 30%f 228 0-100% – – – – region, year
(Deem et al., 2015) 2013 47%d 335 14-83% – – – – age, herd, lifestyle, isolation
(Munyua et al., 2017) 2013 90% NA – – – – – age, region, sex
(Kiambi et al., 2018) 2016-17 – – – – 0.35%d 1421 0-1.2%d region,
(Ommeh et al., 2018) 2016-18 68% 1163 17-87% 1:20 0.95%d 1163 – age, region, sex
(Alagaili et al., 2014) KSAk 1992-2010 87%d 264 77-100% – – – – age, region, year
(Alagaili et al., 2014) 2013 74% 150 66-100% – 25% 202 0-66% age, region
(Alfuwaires et al., 2017) 2015-16 – – – – 14% 44 0-23% yearg
(Harrath and Abu Duhier, 2018) 2016 84% 171 – – – – – age, sex
(Hemida et al., 2014b) 1993 90% 131 73-96% 1:40 – – – region
(Hemida et al., 2013) 2012-13 90% 310 85-94% 1:20 – – – age, region
(Kasem et al., 2018a) 2015-17 – – – – 56% 698 5-85% region, site-type, month, year
(Khalafalla et al., 2015) 2013-14 – – – – 29% 96 – age, site, month
(Sabir et al., 2016) 2014-15 – – – – 0.12% 1309 – –
(Falzarano et al., 2017) Mali 2009-10 88% 562 0-91% • – – – region
(Miguel et al., 2017) Morocco 2015 77%d 343 48-100% 1:20 2%d 343 0-8% region. Further factors assessed in GLMM
(Chu et al., 2015) Nigeria 2015 96% 131 – 1:20 11% 132 – –
(Reusken et al., 2014b) 2010-11 94% 358 82-96% • – – – region
(So et al., 2018) 2016 – – – – 3%d 2529 0-8.4%h age, week tested
(Nowotny and Kolodziejek, 2014) Oman 2013 – – – – 7% 76 – –
(Reusken et al., 2013a) 2013 100% 50 – 1:20 – – – –
(Saqib et al., 2017) Pakistan 2012-15 40% 565 0-83% 1:80 – – – region
(Zohaib et al., 2018) 2015-18 76% 1050 72-80% • 3%d 776 – age, region, sex, lifestyle
(Mohran et al., 2016) Qatar 2014 – – – – 79% 53 67-92% –
(Reusken et al., 2014a) 2014 100% 33 – 1:** 21%d 33 0-58% region
(Raj et al., 2014) 2014 – – – – 2% 53 – –
(Muller et al., 2014) Somalia 1983-4 81%d 86 – 1:80 – – – year
(Muller et al., 2014) Sudan 1984 82% 60 – 1:80 – – – year
(Reusken et al., 2014b) Tunisia 2009 49%d 204 36-100% • – – – region
(Meyer et al., 2014) UAEl 2003 & 13 97% 651 – • – – – year
(Alexandersen et al., 2014) 2005 82% 11 0-100%e 1:12 – – – site
(Wernery et al., 2015a) 2014 93% 853 – – 5% 871 – age
(Wernery et al., 2015b) < 2015 95% 254 – – 0% 254 – age
(Yusof et al., 2015) 2014 – – – – 1.6% 7803 – site-type
(Li et al., 2017; Yusof et al., 2017) 2015 – – – – 29%i 376i – –
(Alexandersen et al., 2014) USAm & Canada 2000-1 0% 6 – 1:12 – – – –
Studies investigating dromedary camel populations linked to human MERS-CoV infection
(Muhairi et al., 2016) UAE 2012 – – – – 4% 1113 farm
(Paden et al., 2018) UAE 2014 – – – – 100% j 6j – –
(Al Hammadi et al., 2015) UAE 2015 100% 8 – 1:40 100% 8 – –
(Kasem et al., 2018b) KSA 2014-16 71% 595 37-100% • 13% 584 0-56% region, age, sex
(Haagmans et al., 2014) Qatar 2013 100% 14 – 1:20 21% 14 – –
(continued on next page)
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Seropositive dromedaries have been found in 20 of the 24 countries
studied. See Table 1 and Fig. 2 for a geographical map of seropositivity.
MERS-CoV seroprevalence was between 71–100% in most country-
level, age-aggregated study populations across West, North and East
Africa and the Middle East. Exceptions included one of the two studies
in Israel (62%), and 4–49% in Bangladesh, the Canary Islands, and
Tunisia as well as one of the two studies in Pakistan and two of the four
studies in Kenya. Samples taken from the large feral camel population
in Australia were seronegative, along with dromedaries in Kazakhstan
and in zoos in Japan, and North America (Reusken et al., 2013a;
Alexandersen et al., 2014; Hemida et al., 2014b; Crameri et al., 2015;
Shirato et al., 2015; Miguel et al., 2016). No other species tested
alongside dromedaries had neutralising antibodies except a small
number of alpacas and llamas living in close quarters with dromedaries
in Israel (David et al., 2018), and 1 sheep in Egypt (Ali et al., 2017a).
Seroprevalence was> 71% in all 4 studies conducted in dromedary
populations epidemiologically linked with human MERS-CoV infection.
3.2. Factors effecting seroprevalence
3.2.1. Age
MERS-CoV seroprevalence was found to increase with dromedary
age in 13 studies (Table 2, Fig. 3). Although seroprevalence was
80–100% in adult dromedaries in most populations across the Middle
Table 1 (continued)
Ref Country Year Seroprevalence RNA prevalence Stratifications
% na Rangeb NTc % na Rangeb
(Farag et al., 2015) Qatar 2014 97% 103 – • 59% 105 – –
Bactrian camels
(Chan et al., 2015) Mongolia 2014 0% 190 – 1:2 0% 190 –
(Liu et al., 2015) Mongolia 2015 0% 200 – 1:2 0% 200 –
(Miguel et al., 2016) Kazakhstan 2015 0% 95 – – – – –
a. total number of camels sampled.
b. range across sub-national locations surveyed.
c. cut off titre to determine positivity if neutralisation test used.
d. we calculated this value from disaggregated values presented by the authors.
e. range given is across site types rather than geographical locations.
f. neutralisation at dilution> 1:80 gave 15% seropositivity but regional range only available for ELISA (Enzyme Linked Immunosorbent Assay) results – reported
accordingly.
g. study also tested different site-types but measured RNA in serum sample rather than nasal swab so this was not included.
h. range is across weeks rather than regions.
i. both (Li et al., 2017) and (Yusof et al., 2017) report RNA prevalence from the same study.
j. unclear whether study found negative camels – it only mentions that 6 camels were tested, found positive and viral genomes were isolated.
k. Kingdom of Saudi Arabia.
l. United Arab Emirates.
m. United States of America.
•neutralisation test limited to a subset of samples or only used to detect presence of high titres.
** No positivity cut-off titre given but all samples had incredibly high titres, and were able to neutralise at dilution>1:1280.
Fig. 2. Map of MERS-CoV seroprevalence in dromedaries. Measures of MERS-CoV seroprevalence in dromedaries, aggregated at the country level. Total sample
size tested is given in parenthesis. Camel density is calculated using FAOSTAT country-level camel population data (FAO, 2016) and World Bank data on country
surface area (World Bank, 2016) *value calculated by us from disaggregated sub-national measures of seroprevalence. Red text highlights studies conducted in
dromedary populations in response to an epidemiologically linked human MERS-CoV infection. (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
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Table 2
Studies reporting seroprevalence stratified by age of dromedary.
Country Stratified seroprevalencec Reported trend Reported significance Ref.
Bangladesh <2yrs 9% (n=11)
≥2yrs 36% (n= 44)
Higher in camels > 2yrs Not significant (Islam et al., 2018)
Burkina Faso, Ethiopia and
Morocco
Generalised Linear Mixed Model
(n=1500)
Increase with age p=0.032 (Miguel et al., 2017)
Egypt <2yrs 52% (n=81)
≥2yrs 87% (n= 950)
Higher in camels > 2yrs p < 0.0001 (Ali et al., 2017a)
Ethiopia 1- ≤2yrs 93% (n= 31)
2-13yrs 97% (n= 157)
None Not significant (Reusken et al., 2014b)
Iraq <2yrs 89% (n=44)
>2yrs 84% (n=136)
2-4yrs 81% (n=58)
>4yrs 86% (n=78)
Lower in camels 2-4yrs compared with
< 2yrs
Not significant (Thwiny et al., 2018)
Jordan ≤2yrs 74%a (n= 31a)
>2yrs 100%a (n=14a)
ELISA ratio higher in camels > 3yrs Significant p=NA (van Doremalen et al., 2017)
Kenya <2yrs 29%a (n=141a)
>2yrs 61% (n=194)
<6m 39% (n=61)
6m-2yrs 21% (n=80)
Higher in camels > 2yrs than < 6m p < 0.05 (Deem et al., 2015)
Kenya 1-4yrs 73% (n= 285)
>4yrs 98% (n = 592)
4-6yrs 98% (n=116)
6yrs 98% (n=476)
Higher in camels > 4yrs p < 0.05 (Munyua et al., 2017)
Kenya <4yrs 36%(n= 319)
>4yrs 80% (n = 830)
>4 < 7yrs 59% (n=70)
>7yrs 82% (n=760)
Higher in camels > 7yrs p < 0.001 (Ommeh et al., 2018)
KSA ≤2yrs 55% (n= 104)
>2yrs 95% (n=98)
Higher in camels > 2yrs p < 0.0001 (Alagaili et al., 2014)
KSA ≤2yrs 73% (n= 77)
>2yrs 93% (n=187)
Higher in older animals Not presented (Alagaili et al., 2014)
KSA 1-2yrs 93% (n= 71)
3-5yrs 78% (n= 100)
Lower in camels > 2yrs p=0.03 (Harrath and Abu Duhier, 2018)
KSA <1 yr 72% (n= 65)
>1 yr 95%a (n= 245)
1-3yrs 95% (n=106)
4-5yrs 97% (n=76) > 5yrs 92% (n=63)
Higher in camels > 1 yr p < 0.01 (Hemida et al., 2013)
Mali < 2yrs 83% (n=NAb)
>2yrs ∼90%d (n = NAb)
3-8yrs 91% (n=NAb)
9-16yrs 88% (n=NAb)
None Not significant (Falzarano et al., 2017)
Pakistan ≤3yrs 58% (n= 177)
>3yrs 79% (n = 873)
3.1-10yrs 79% (n=712)
>10yrs 81% (n=161)
Lower in animals ≤3yrs p < 0.001 (Zohaib et al., 2018)
Pakistan ≤2yrs 29% (n= 89)
>2yrs 41%(n = 476)
2.1-5yrs 30% (n= 208)
5.1-10yrs 51% (n=180)
>10yrs 49%(n=88)
Higher in older animals p < 0.001 (Saqib et al., 2017)
UAE <1 yr 85% (n= 108)
>1 yr 96%a (n= 650)
2-4yrs 97% (n=340)
>4yrs 96% (n=310)
Lower in calves < 1 yr p < 0.05 (Wernery et al., 2015a)
UAE <1 yrs 84% (n= 121)
>1 yrs 99% (n= 133)
0-3m 75% n=32)
4m 79% (n=14)
5-6m 89% (n=46)
7-12 90% (n=29)
Increase with age Not tested (Wernery et al., 2015b)
Studies investigating dromedary camel populations linked to human MRS-CoV infection
KSA ≤2yrs 58% (n=25)
>2yrs 81% (n= 344)
2.1-4yrs 77%c (n= 156)
4.1-6yrs 81%c (n=98)
>6yrs 87%c (n= 90)
Higher in camels > 2yrs p=0.003 (Kasem et al., 2018b)
The bold type highlights the aggregated seroprevalence values presented graphically in figure 3.
a Age stratified results were calculated by us, using disaggregated results presented by authors.
b Number of animals in each age class not supplied.
c n = the total number of dromedaries sampled.
d Seroprevalence in>2yrs estimated under the assumption that age classes 3-8yrs and 9-16yrs are the same size.
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East and the horn of Africa, juveniles in the same populations were
repeatedly found to have lower and more variable seroprevalence (˜40-
90%). One study disaggregated calf age through the first year of life. In
this setting (UAE) calves had high seroprevalence increasing with age to
90% in 7–12-month-olds (Wernery et al., 2015b).
3.2.2. Geographic location
Although MERS-CoV seroprevalence is consistently high across
West, North, East Africa and the Middle East at the country level, some
studies measured considerable within-country variation in ser-
oprevalence, particularly in Africa (ranges given in Table 1). In Kenya
all three studies that presented sub-nationally disaggregated results
showed seroprevalence to vary greatly by province. Tunisia, Morocco
and Mali also showed considerable regional seroprevalence variation.
Less regional variation in seroprevalence was observed within Middle
Eastern countries.
Fig. 3. Age stratified seroprevalence.
Measures grouped by available stratification
and arranged in order of increasing adult ser-
oprevalence. Bars indicate 95% confidence in-
tervals, calculated by us when not stated in the
study, if age class size was available (not
available for the population in Mali). *in-
dicates that calves< 1-year-old were not in-
cluded. **indicates that the study was con-
ducted in dromedary populations in response
to an epidemiologically linked human MERS-
CoV infection.
Fig. 4. Map of prevalence of active MERS-CoV infection in dromedaries. Measures of MERS-CoV RNA prevalence in dromedaries, aggregated at the country level.
Total sample size tested is given in parenthesis. Camel density is calculated using FAOSTAT country-level camel population data (FAO, 2016) and World Bank data
(World Bank, 2016) on country surface area. *value calculated by us from disaggregated sub-national measures of RNA prevalence. Red text highlights studies
conducted in dromedary populations in response to an epidemiologically linked human MERS-CoV infection. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
A. Dighe, et al. Epidemics xxx (xxxx) xxxx
6
3.2.3. Sample population characteristics
Several studies found imported animals to have significantly higher
seroprevalence than their locally bred counterparts (Gutierrez et al.,
2015; Ali et al., 2017a, b; Islam et al., 2018). Dromedaries sampled at
markets, abattoirs and quarantine sites had higher seroprevalence than
those in farms, villages and research facilities (Ali et al., 2017a, b; van
Doremalen et al., 2017; Islam et al., 2018). In some cases, dromedary
origin varied with the type of site sampled suggesting confounding.
In a study conducted across Burkina Faso, Morocco and Ethiopia,
dromedaries used for milk and meat had higher seroprevalence than
those used for transport (Miguel et al., 2017). In most of the studies that
stratified by sex, little difference was seen, but in Kenya females had
statistically significantly higher seroprevalence than males (93% vs.
81% in one study (Munyua et al., 2017), and 74% vs. 54% in another
(Ommeh et al. 2018)) whereas males had significantly higher ser-
oprevalence in Egypt and in KSA (72% and 84% in males vs. 66% in
females) (Ali et al., 2017b; Kasem et al., 2018b).
Large and medium herd-size was a significant risk factor for ser-
opositivity across Burkina Faso, Morocco and Ethiopia, as well as no-
madic and sedentary husbandry systems as opposed to a mixed lifestyle
(Miguel et al., 2017). Conversely, in Kenya there was a non-statistically
significant trend for smaller herds to have higher seroprevalence (Deem
et al., 2015). Two other studies in Kenya showed higher seroprevalence
in nomadic herds compared with those kept on ranches or those with
agro-pastoralist management. However, ranches were in a different
region from nomadic herds and the sample size for agro-pastoralist
management was very small (Corman et al., 2014; Munyua et al.,
2017).
3.3. Prevalence of active MERS-CoV infection – cross-sectional studies
Our search found that dromedary populations in 16 countries have
been tested for MERS-CoV RNA, 13 of which report positive results
indicating active infection. These include KSA (0.12–56%) (Alagaili
et al., 2014; Khalafalla et al., 2015; Sabir et al., 2016; Alfuwaires et al.,
2017; Kasem et al., 2018a, b), UAE (0–29% (Wernery et al., 2015a, b;
Yusof et al., 2015; Li et al., 2017; Yusof et al., 2017) or 0–100% if
dromedaries epidemiologically linked to human MERS-CoV cases are
included(Al Hammadi et al., 2015; Muhairi et al., 2016; Paden et al.,
2018)), Qatar (22–79%) (Haagmans et al., 2014; Reusken et al., 2014a;
Farag et al., 2015; Mohran et al., 2016), Oman (7%) (Nowotny and
Kolodziejek, 2014), Iraq (15%) (Al Salihi and Alrodhan, 2017), and
Jordan (62%) (van Doremalen et al., 2017), as well as Egypt (4–15%)
(Chu et al. 2014, Ali et al., 2017a, b), Ethiopia (10%) (Miguel et al.,
2017), Kenya (0.35-0.95%) (Kiambi et al., 2018; Ommeh et al., 2018),
Nigeria (3–11%) (Chu et al., 2015; So et al., 2018), Burkina Faso (5%)
(Miguel et al., 2017), Morocco (2%) (Miguel et al., 2017), and Pakistan
(3%) (Zohaib et al., 2018). See Fig. 4 for a map of RNA prevalence, and
Table 1). Despite moderate seropositivity, surveys have not detected
active MERS-CoV infection in the dromedary populations of Bangladesh
or Israel (David et al., 2018; Islam et al., 2018). RNA prevalence in
dromedary populations linked to human cases was similar to more
randomly sampled populations in the same country, with the exception
of two small outbreak studies in the UAE which found 100% of epi-
demiologically linked dromedaries to be infected (Al Hammadi et al.,
2015; Paden et al., 2018).
3.4. Factors affecting prevalence of infection
3.4.1. Age
Age stratified studies in KSA and Jordan found that juveniles had a
higher RNA-positivity than adults (Alagaili et al., 2014; van Doremalen
et al., 2017; Kasem et al., 2018b). RNA-positivity also had an inverse
association with age in dromedaries across Morocco, Burkina Faso and
Ethiopia (Miguel et al., 2017). Two studies in Egypt measured similar
positivity rates between juveniles and adults (Ali et al., 2017a, b).
3.4.2. Sample population characteristics
Higher prevalence of RNA shedding was found in imported animals
by three studies in Egypt, however site-type is a potential confounder,
with local camels being sampled from farms and villages, whilst im-
ported animals were sampled in markets, quarantine centres and
abattoirs (Chu et al., 2014; Ali et al., 2017a, b). A study in KSA sampled
both local and imported dromedaries within live animal markets found
that locally-reared animals had significantly higher prevalence of viral
shedding (Sabir et al., 2016). Overall, three studies reported abattoirs
and one reported wholesale markets to be associated with an increase in
measured prevalence of shedding compared to villages, farms and
quarantines (Yusof et al., 2015; Sabir et al., 2016; Alfuwaires et al.,
2017; Miguel et al., 2017). Much like seroprevalence, RNA positivity
was significantly higher in dromedaries bred for meat or milk compared
with those used as transport in Burkina Faso, Morocco and Ethiopia,
and shedding was higher amongst females, albeit sex and function were
highly correlated (Miguel et al., 2017).
3.4.3. Potential temporal trends
Five studies measured RNA prevalence at a defined site at multiple
points in time. Animals were not themselves sampled longitudinally.
Three studies in Egypt and KSA showed a clear peak in prevalence of
viral RNA shedding from December to May (Khalafalla et al., 2015; Ali
et al., 2017b; Kasem et al., 2018a). The fourth, conducted in wholesale
markets in KSA, saw lower rates infection during July and August, and
higher positivity in December (Sabir et al., 2016). At an abattoir in
Nigeria, no infection was seen from October to mid-January, with
prevalence of infection peaking in February after which no more sam-
ples were taken (So et al., 2018).
3.5. Evidence of infection and immunity from longitudinal studies
We found 10 longitudinal studies describing 9 incidences of natural
infection on farms and in quarantine facilities – 1 in Egypt (Ali et al.,
2017b), 4 in KSA (Azhar et al., 2014; Hemida et al., 2014a; Memish
et al., 2014; Hemida et al., 2017a), 5 in UAE (Al Hammadi et al., 2015;
Wernery et al., 2015a; Meyer et al., 2016; Muhairi et al., 2016; Yusof
et al., 2017) and 1 study taking monthly samples of 430 dromedaries in
Kenya (Kiambi et al., 2018).
3.5.1. Duration of viral shedding
Four studies of natural infection measured viral shedding in dro-
medaries at approximately weekly intervals. The maximum time
window in which all consecutive nasal samples taken were positive for
MERS-CoV RNA ranged from 7 to 45 days across published studies, with
most positive animals becoming negative within 2 weeks (Al Hammadi
et al., 2015; Wernery et al., 2015a; Muhairi et al., 2016; Yusof et al.,
2017). All available studies followed animals that were found to be
MERS-CoV RNA positive at the first instance of sampling and the
duration of shedding prior to sampling is unknown. Further to this,
intermittent RNA shedding, and evidence of potential rapid reinfection/
coinfection has been observed (Muhairi et al., 2016; Yusof et al., 2017).
3.5.2. Evidence of reinfection
Three studies have found dromedaries to be shedding MERS-CoV
RNA despite having high antibody titres months or weeks prior to de-
tectable infection. Both older animals whose antibodies reflect past
exposure (Meyer et al., 2016; Ali et al., 2017b; Hemida et al., 2017a),
and young calves whose high antibody titres were maternally-acquired
immediately post-partum, became infected (Meyer et al., 2016).
One study directly observed recurring infection amongst a herd of
dromedaries in Egypt. Four animals were shedding 1–3 months prior to
a herd-wide epidemic in which they were RNA-positive once more (Ali
et al., 2017b). Sequenced isolates from a market in UAE showed lineage
switching from week to week which is also supportive of rapid re-
infection or coinfection in calves (Yusof et al., 2017).
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Longitudinal studies also indicated that maternally acquired im-
munity may offer some protection. In both studies of calf-mother-pairs
conducted in UAE, MERS-CoV infection became highly prevalent in
calves between 4–6 months of age when maternally-acquired antibody
titres had waned (Wernery et al., 2015a; Meyer et al., 2016). Samples
from reinfected animals have been found to have lower viral loads,
suggesting that past infection may ameliorate future infections (Hemida
et al., 2017a). Viral load and probability of isolating infectious virus
were greater when sampling calves, than adults (Meyer et al., 2016;
Ommeh et al., 2018).
4. Discussion
The results of our systematic review show that MERS-CoV circulates
widely in dromedaries across the Middle East and Africa, but trans-
mission varies spatially, and temporally. The sub-national range of
MERS-CoV seroprevalence appears to be larger in countries outside of
the Arabian Peninsula. Within-country variation in seroprevalence is
potentially indicative of differences in transmission dynamics, meaning
vaccine strategy evaluation and mathematical modelling will need to be
conducted at a sub-national resolution.
The rise of MERS-CoV seroprevalence from 40 to 90% in juveniles,
to 80–100% in adult dromedaries across much of West, North and East
Africa and the Middle East, is signature of an endemic disease where the
probability of infection increases with time. High seroprevalence in
calves< 1-year-old in some populations in UAE and KSA suggests high
transmission intensity in the Arabian Peninsula, with most dromedaries
becoming infected during the first year of life, though maternally ac-
quired antibodies may contribute to seropositivity in young calves
(Hemida et al., 2013; Wernery et al., 2015a, b). The age-dependent
seroprevalence values synthesised here should be used to fit models of
MERS-CoV transmission in dromedaries and elucidate the likely trans-
mission intensity of the virus in the Middle East and in Africa – a key
parameter for estimating vaccination impact. Reporting finer age stra-
tification of young dromedaries would allow a better comparison of
transmission intensity in different regions through fitting models of
seroconversion.
Despite locally-acquired human cases predominantly being reported
within the Arabian Peninsula, the major unilateral trade of camels from
the Horn of Africa to the Arabian Peninsula (Younan et al., 2016) means
that the endemicity of MERS-CoV in African dromedary populations has
implications for the scope of control programs. Thus far, MERS-CoV
isolates have been grouped into 3 clades based on genetic similarity. In
the most recent phylogeny, viruses isolated in Africa (Egypt, Ethiopia,
Morocco, Nigeria, Burkina Faso and most recently Kenya) have all been
classified into Clade C (with West African isolates comprising sub-clade
C1(Chu et al., 2018)), while isolates from the Arabian Peninsula have
only ever been classed as clades A or B (Chu et al., 2014, 2015; Chu
et al., 2018; Kiambi et al., 2018). Spike region sequences from Pakistan
are similar to those from the Arabian Peninsula (Zohaib et al., 2018).
Virus neutralisation tests have shown that isolates from different clades
are antigenically similar and therefore that it is likely that a single clade
vaccine would be cross-protective against other clades too (Chu et al.,
2018). More extensive testing to confirm cross-protection would be
useful for vaccine development. Phenotypically, sub-clade C1, so far
restricted to West Africa, does differ from other isolates tested in that it
is less able to reproduce in humanised mice and ex-vivo human lung
tissue (Chu et al., 2018). This difference did not apply to other clade C
isolates so cannot explain the lack of reported cases in Africa. Further
investigation of the geographical restrictions of MERS-CoV clades
would help clarify the extent to which MERS-CoV circulates inter-
continentally.
Age-dependent seroprevalence patterns suggest that the higher
prevalence of viral shedding in juveniles compared with adults is likely
due to immunological naivety. The age-distribution of reported infec-
tions synthesised here, suggests that contact with juveniles may pose
greater risks of human transmission than adults, making them potential
targets for vaccination. However, frequency of human contact with
dromedaries may also be animal-age-dependent (Wernery et al.,
2015a). Calf-focused vaccination may reduce the overall number of
dromedary infections but, the reduced risk of exposure would mean
that any remaining infections would likely occur at an older age than in
the absence of vaccination. It will therefore be important to further
investigate the age-dependency of human-dromedary contact patterns
and how these vary in different countries and husbandry systems.
Vaccination strategies should be evaluated, not only on their likely
impact on prevalence of active infection in dromedaries, but also on the
age-distribution of infections.
Mapping the movement of dromedaries is necessary to understand
the underlying spatial transmission dynamics of MERS-CoV. The mixing
of dromedaries underpins interaction between infectious and suscep-
tible individuals and therefore the dynamics of MERS-CoV transmis-
sion. Live markets and abattoirs which both had higher prevalence of
RNA shedding compared to other site-types in multiple studies, are key
locations for animal mixing (Perera et al., 2013; Yusof et al., 2015;
Sabir et al., 2016; Miguel et al., 2017). Quantitative data describing the
movement and trading patterns of dromedary populations will be es-
sential for informing models and considering where potential vaccina-
tion should take place. A role for markets as drivers of disease dis-
semination is characteristic of other zoonotic diseases such as avian
influenza (Gilbert et al., 2014; Fournié et al., 2016).
Move evidence is required to establish whether MERS-CoV infection
in dromedaries is seasonal. The temporal studies in this review ob-
served higher prevalence of active infection between December and
June (Khalafalla et al., 2015; Sabir et al., 2016; Ali et al., 2017b; Kasem
et al., 2018a). These were conducted in Egypt and KSA where dro-
medary calving occurs between October and February (Almutairi et al.,
2010; Hemida et al., 2017b; Ali et al., 2018), and Nigeria which has a
similar calving season (Abdussamad et al., 2011). Assuming seasonal
calving was driving the trend, and calves become susceptible between
4–6 months (Wernery et al., 2015a; Meyer et al., 2016), we might ex-
pect the number of susceptible dromedaries be higher between January
and May – which overlaps with the peaks observed. If infection is
driven by seasonal calving, vaccination would need to occur annually
prior to the infection of newly susceptible calves. Based on phylogenetic
analysis of MERS-CoV genomes isolated from humans and dromedaries,
a seasonal period of elevated risk of zoonotic transmission has been
estimated to exist from April through to July (Dudas et al., 2018),
however, this is not consistent with the epidemiology of primary human
MERS-CoV cases reported to the World Health Organisation (WHO)
since 2012 (Al-Tawfiq and Memish, 2018). As well as seasonal calving,
environmental factors have also been hypothesised to be associated
with zoonotic transmission (measured as the incidence of primary
human cases). Lower temperatures and humidity were found to be as-
sociated with higher numbers of reported primary human MERS cases
in KSA (Gardner et al., 2019). Further investigation of potential sea-
sonality has been highlighted as a priority by the FAO-OIE-WHO MERS-
CoV Technical Working Group (FAO-OIE-WHO MERS-CoV Technical
Working Group, 2018).
The results of longitudinal studies included in this review demon-
strate re-infection of dromedaries despite high titres of MERS-CoV
specific antibodies being present in their sera. Unfortunately, the de-
gree and duration of protection afforded by maternally-acquired anti-
bodies and those acquired from infection is unclear. Informative sur-
veys of a better proxy for protective immunity in dromedaries would
improve the accuracy of models of reinfection and the likely effects of
vaccination.
Although we found maximum duration of RNA shedding to range
from 7 to 45 days across studies, intermittent shedding or rapid re-
infection has been seen to occur for 6 weeks which complicates inter-
pretation of RT-PCR derived RNA shedding results for infectious period.
A controlled challenge study in 4 dromedaries performed daily
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sampling and saw the maximum duration of shedding to be 35 days
post inoculation, with infectious virus (as determined by plaque assay)
isolatable for the first 7 days (Adney et al., 2014). However, the bio-
logical relevance of the challenge dose is not known. More frequent
sampling that includes genotyping and captures of the onset of shed-
ding is needed to more accurately estimate the duration of infectious-
ness following a single natural infection.
Limitations of our study include that a single author completed the
systematic search and data extraction, and that we only included
published literature thereby introducing potential publication bias. The
available studies exhibit differences in study design, criteria for ser-
opositivity, sample-site type and sample population characteristics.
Some studies report that the latter two variables are associated with
statistically significant differences in seroprevalence or prevalence of
infection within individual studies (Corman et al., 2014; Yusof et al.,
2015; Sabir et al., 2016; Ali et al., 2017a, b; Miguel et al., 2017; van
Doremalen et al., 2017). These heterogeneities made quantitative
pooling inappropriate.
Available published studies do not include results from camel dense
regions of northern Africa or Rajasthan, India, and Yemen. In addition
to the countries included in this systematic review of the published
literature, OIE has received reports of RNA positive camels in Iran and
Kuwait (OIE - World Organisation for Animal Health, 2014a; OIE,
World Organisation for Animal Health, 2014b). Members at WHO and
the Food and Agriculture Organisation of the United Nations (FAO),
together with country counterparts are planning and/or implementing
further RNA testing studies in several countries in Africa (e.g. Ethiopia,
Kenya, Egypt, Somalia, Sudan, Algeria and Morocco), the Middle East
(e.g. Jordan), and South Asia (e.g. Pakistan) (personal communication,
Maria D. Van Kerkhove).
Implementing MERS-CoV vaccination in dromedaries will be chal-
lenging. First, since MERS-CoV infection does not cause significant
disease in camels, a dromedary vaccine will be implemented solely for
the purpose of preventing human infections. While there are several
examples of vaccinating animals to protect humans from infection
(Monath, 2013) (e.g., low pathogenic avian influenza (Busani et al.,
2009; Halvorson, 2009), Hendra virus (Broder et al., 2013), and rabies
(Lavan et al., 2017)), overcoming cultural and economic concerns of
camel owners and the camel industry will require strong advocacy with
owners, industry and political leaders in countries with high dromedary
density. It is critical that any animal vaccine will not harm the liveli-
hoods of animal owners and those involved in the selling, trading or
recreational use of the animals. Second, despite ample scientific evi-
dence that MERS-CoV is a zoonotic virus and can transmit between
camels and humans (FAO-OIE-WHO MERS Technical Working Group,
2018), in some contexts there is still reluctance to accept that dro-
medaries play a role MERS transmission. While member states are
working with Ministries of Health, Ministries of Agriculture, and com-
munities to address this, a dromedary vaccine that can be implemented
with existing accepted dromedary vaccines would be preferential.
Third, at this stage in their development, it is not clear whether a
dromedary vaccine will provide adequate protection against re-infec-
tion. Available studies (Haagmans et al., 2016; Alharbi et al., 2017)
suggest that a dromedary vaccine may greatly reduce viral shedding,
rather than providing sterilizing immunity. The infectiousness of dro-
medaries shedding low levels of the virus is currently uncertain. Genetic
diversity is unlikely to demand a vaccine based on more than one clade
due to antigenic similarity and cross-protection. Further discussion of
these wider challenges of implementing a MERS-CoV vaccine in dro-
medaries, would benefit from being informed by a clearer picture of
what an epidemiologically optimal vaccination strategy would involve.
5. Conclusions
Our findings provide strong evidence that MERS-CoV is endemic in
dromedary populations across much of West, North, East Africa and the
Middle East, in agreement with the similar systematic review conducted
in parallel with our own (Sikkema et al., 2019).
In addition, our findings highlight several epidemiological char-
acteristics of MERS-CoV that must be considered in the design of MERS-
CoV animal vaccination strategies. Calves are likely to play a central
role in sustaining circulation of MERS-CoV and should be a target of
potential dromedary vaccination. However, the potential for mass
vaccination of calves to change the age distribution of infected in-
dividuals should be investigated through mathematical modelling of
transmission dynamics in dromedary populations and considered in the
context of age-dependent human-camel contact frequency patterns.
Sites where dromedaries mix may also play a role in driving transmis-
sion. A better understanding of dromedary husbandry and trade pat-
terns, as well as quarantine facilities, is needed to identify where dro-
medaries become infected with MERS-CoV – critical for focussing
potential vaccination strategies both geographically and within the
dromedary camel value chain. Although in a few studies, prevalence of
infection appears to peak in the first half of the year, which may be
facilitated by the increase in susceptible animals after the calving
season, further studies are needed to confirm this. More longitudinal
studies are required to investigate the temporal dynamics of viral
shedding and immunity in the animal host and should ideally be cap-
able of distinguishing co-circulating MERS-CoV lineages.
The remaining gaps in our understanding of MERS-CoV transmis-
sion dynamics in dromedary populations are in agreement with the
prioritized research outlined in the FAO-OIE-WHO Technical Working
group report (FAO-OIE-WHO MERS Technical Working Group, 2018)
and must be addressed to obtain a clearer picture of what an optimal
epidemiological vaccination strategy would involve, as well as its likely
impact, before wider challenges of implementation can be considered
further.
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